

Clinical Trial for GI Carcinoid Patients Recruiting through September

Gastrointestinal carcinoid patients who have tumors that either are not suitable for standard treatment or are not responding to standard treatment have the opportunity to enroll in a **Phase I/II clinical trial** conducted by [Tekmira Pharmaceuticals](#). Enrollment is expected to complete by September 30. Centers in Arizona, Florida, Iowa, Massachusetts, Michigan, Minnesota, and Texas are participating in the study.



The study drug contains a type of **man-made molecule related to DNA called siRNA (small interfering RNA)**. This siRNA is designed to reduce the levels of a protein called **PLK1 (polo-like kinase 1)** inside tumor cells. Because the PLK1 protein is present at high levels in dividing cancer cells it is expected that **by reducing PLK1 the study drug may be able to slow down or stop the cancer cells from multiplying**. (pictured below is the structure of PLK1)



Participants in the study will **undergo 6 cycles of investigational treatment**, which are **each one month long**. A **radiological assessment of participants' tumors** will take place at the end of the second month to determine if the cancer is stable, responding to treatment, or growing.

The participating centers are:

Scottsdale Healthcare, Scottsdale, Arizona

Contact Joyce Schafer ■ 480-323-1339

joschaffer@shc.org

Mayo Clinic, Scottsdale, Arizona

Mayo Clinic, Rochester,

Clinical Trial for GI Carcinoid Patients Recruiting through September

Published on The Carcinoid Cancer Foundation (<http://www.carcinoid.org>)

Minnesota

Contact: Clinical Trials Office ■ 507-538-7623

University of Iowa, Holden Cancer Center, Iowa

Contact Julie Schlabaugh ■ 319-356-4797

julie-schlabaugh@uiowa.edu

Moffitt Cancer Center, Tampa, Florida

Contact Helen Jump ■ 813-745-4834

helen.jump@moffitt.org

University of Michigan Comprehensive Cancer Center, Michigan

Contact: Julio Garcia-Castro ■ 734-647-9437

jgarcia@med.umich.edu

Dana Farber Cancer Institute, Boston, Massachusetts

Contact: Bon Lam ■ 617-632-5261

BonM_Lam@DFCI.HARVARD.EDU

Westchase Oncology Center, Houston, Texas

Contact: Dr. Mohammad Ali Hamidi ■ 713-341-3204

mhamidi@exceldiagnostics.com

For more information about the study, including eligibility requirements, [click here](#) or call Tekmira, toll-free, at 1-844-419-3258. To get information regarding reimbursement for lodging, meals and the available travel stipend please contact the treating center nearest you.

To learn more about **Tekmira Pharmaceuticals**, visit <http://www.tekmira.com>.

Source URL:

<http://www.carcinoid.org/content/clinical-trial-gi-carcinoid-patients-recruiting-through-september>